title: Reduced glutathione protects against cisplatin-induced neurotoxicity in rats.
abstract: Reduced glutathione (GSH) is reported to diminish cisplatin-induced neurotoxicity, and it was for this reason that we studied GSH in an animal model of cisplatin neuropathy. The neuropathy was evaluated by measuring the sensory nerve conduction velocity (SNCV) in young adult Wistar rats. GSH injections (i.v.) were given twice weekly, within five minutes before cisplatin was injected (i.p.). In a first experiment GSH (500 mg/kg) in combination with a low-dose cisplatin treatment (1 mg/kg, 10 weeks) was investigated. Animals treated with cisplatin and placebo developed a neuropathy (SNCV at week 10: age controls, 61.9 m/s; cisplatin alone, 44.2 m/s), whereas rats treated with cisplatin and GSH did not (SNCV, 61.9 m/s). The same dose of GSH was used in combination with a high-dose cisplatin schedule (2 mg/kg, 5 weeks' treatment plus 5 weeks' recovery). Again, GSH protected animals against the development of neuropathy (SNCV at week 10: age controls, 61.9 m/s; cisplatin alone, 50.6 m/s; cisplatin plus GSH, 61.1 m/s). In another experiment four lower doses of GSH (25, 50, 100, and 200 mg/kg) were tested in combination with the low-dose cisplatin protocol (1 mg/kg, 11 weeks). The cisplatin group developed a neuropathy (SNCV at week 11: cisplatin alone, 50.2 m/s; age controls, 60.6 m/s). Only the dose of 200 mg GSH/kg was found to protect against the development of a neuropathy (SNCV, 61.0 m/s). In an antitumor study GSH administered at 300 mg/kg in combination with cisplatin at 1.5 mg/kg did not diminish the curative effect of cisplatin. We conclude that GSH prevents cisplatin-induced neuropathy and that it should be investigated further in the clinic.
authors.affiliation: Rudolf Magnus Institute, Department of Medical Pharmacology, Utrecht State University, The Netherlands.
authors.forename: F P
authors.initials: FP
authors.lastname: Hamers
authors.forename: J H
authors.initials: JH
authors.lastname: Brakkee
authors.forename: E
authors.initials: E
authors.lastname: Cavalletti
authors.forename: M
authors.initials: M
authors.lastname: Tedeschi
authors.forename: L
authors.initials: L
authors.lastname: Marmonti
authors.forename: G
authors.initials: G
authors.lastname: Pezzoni
authors.forename: J P
authors.initials: JP
authors.lastname: Neijt
authors.forename: W H
authors.initials: WH
authors.lastname: Gispen
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology; D001835:Body Weight / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000633:toxicity*; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004594:Electrophysiology; D005978:Glutathione / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy; D009422:Nervous System Diseases / Q000139:chemically induced / Q000517:prevention & control*; D009431:Neural Conduction / Q000187:drug effects; D009475:Neurons, Afferent / Q000187:drug effects / Q000502:physiology; D051381:Rats; D017208:Rats, Wistar
chemical_list: D005978:Glutathione; D002945:Cisplatin